NEW YORK (GenomeWeb) – GATC Biotech will offer its clients full access to Qiagen's Ingenuity Variant Analysis solution under a non-exclusive deal announced today by Qiagen.
Under the terms of the deal, GATC clients will also have access to interpretation services. Ingenuity Variant Analysis is a bioinformatics platform that enables laboratories to evaluate data generated by high-throughput next-generation sequencing technologies. It filters genetic variants in a cloud-based environment to identify those most likely to cause disease.
Financial and other terms of the deal were not disclosed.
"Integrating this software tool with our InView Human Exome product enables us to provide world-class data analysis for end users of NGS, including clinical and laboratory geneticists and other professionals investigating diseases," GATC COO Marcus Benz said in a statement.